April 18th 2025
The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Oxford Biomedica Signs Agreement with Vaccines Manufacturing and Innovation Centre
June 12th 2020Oxford Biomedica, has signed a collaboration agreement with the not-for-profit organization, the Vaccines Manufacturing and Innovation Centre, to provide the UK with its first strategic vaccine development and advanced manufacturing capability.
HCATS, apceth Biopharma Form Strategic Manufacturing Agreements with bluebird bio
May 13th 2020Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma entered into long-term development and manufacturing services agreements for the clinical and commercial supply of multiple bluebird bio therapies.